Jenburkt Pharmaceuticals Ltd — Important, 05-05-2026: Company Update

Jenburkt Pharmaceuticals' Board approved the financial results for the quarter and full-year. The company reported ₹44.63 Cr in Q4 revenue from operations and ₹168.74 Cr for the full year, with Q4 profit after tax at ₹10.85 Cr and full-year profit at ₹34.74 Cr. Basic EPS for the year stood at ₹78.71. A dividend of ₹220.70 (207%) per equity share was declared for FY 2025-26. The 41st Annual General Meeting is set for September 4, 2026. The board also approved the re-appointment of Shri Dilip H. Bhuta as Whole-time Director and CFO for a five-year term starting April 1, 2027.